Podcasts about frcpc

Comments or feedback? Send us a text! Dr. Chris Taplin,a psychiatrist and founder of Ottawa's TMS Life clinic, joins us for a deep dive into one of the most promising frontiers in psychiatric care: Transcranial Magnetic Stimulation, or TMS. As clinicians, many of us have encountered the heartbreak of treatment-resistant depression — watching clients struggle despite best-practice psychotherapy and pharmacology. TMS offers a non-invasive, evidence-based alternative that is reshaping how we approach these cases. In this conversation, we unpack the science, patient experience, clinical decision-making, and broader implications of this technology. Whether you're a skeptic, a curious clinician, or already working with neuromodulation, I think you'll find this a thoughtful, grounded look at where TMS fits in the future of mental health treatment.Topics We Cover:

Vijay Ramaswamy, MD, PhD, FRCPC - Spotting Rare Disease in Practice: Neurofibromatosis Type 1 With Plexiform Neurofibromas

Vijay Ramaswamy, MD, PhD, FRCPC - Spotting Rare Disease in Practice: Neurofibromatosis Type 1 With Plexiform Neurofibromas

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

Animatrice : Dre Emma Glaser, MD-MSc CMFC, médecin de famille, GMF-U Bordeaux Cartierville Invités :Dr. Julie St-Pierre, MD, PhD, FAHA, FRCPC, pédiatre et lipidologue, professeure agrégée de pédiatrie à la Faculté de Médecine de l'Université McGillCarine El-Khoury, résidente de 2e année en médecine familiale au GMF-U de Bordeaux-CartiervilleÉmilie Renaud-Charest, résidente de 2e année en médecine familiale au GMF-U de Bordeaux-CartiervilleCharlotte Maheu-Savard, résidente de 2e année en médecine familiale au GMF-U de Bordeaux-CartiervilleObjectifs :Présenter un guide clinique des meilleures approches pour la gestion de l'obésité infantile en bureau en première ligne, compte tenu de la difficulté à mettre en place des interventions efficaces, auxquelles les patients et leurs parents adhèrent, afin d'améliorer les paramètres de santé chez les patients de 6 à 12 ans ayant développé de l'obésité infantile.Messages clés :Nouvelle définition de l'obésitéL'IMC n'est maintenant plus le seule critère pour définir l'obésité depuis janvier 2025. Il y a maintenant 2 classes d'obésité distinctes, l'obésité pré clinique et l'obésité clinique. Le tour de taille est aussi davantage mis en avant-plan. L'obésité pré clinique se définit par un excès de poids n'ayant pas d'impact significatif sur la santé ni d'atteinte sur le fonctionnement des organes. L'obésité clinique est une maladie induite par l'impact spécifique d'une adiposité excessive sur divers organes. Un exemple serait la stéatose hépatique ou la dyslipidémie.Approche par objectifs pour l'atteinte des saines habitudes de vie (et non pour l'atteinte d'un poids donné)Viser l'atteinte de courts objectifs précis et réalisables à différents égards et non une perte de poids nécessairement. Suivre les patients régulièrement pour s'assurer d'atteindre ces objectifs. Ex : Cesser graduellement la consommation de jus de fruits.Les 4 points cardinaux pour intervenir en obésité pédiatrique sont le sommeil, l'activité physique, l'alimentation et le temps d'écran.

Denise Black, MD, FRCSC / Marla Shapiro, C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, MSCP - Navigating the Menopause Transition With Your Patients: Experts Answer Key Questions

Denise Black, MD, FRCSC / Marla Shapiro, C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, MSCP - Navigating the Menopause Transition With Your Patients: Experts Answer Key Questions

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DWJ865. CME credit will be available until April 2, 2026.BTK Inhibition as an MS Treatment Strategy: Targeting Smoldering Neuroinflammation In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Sanofi.Disclosure information is available at the beginning of the video presentation.

Join Executive Producer and Host Shravani Durbhakula, MD, MPH, MBA, and Co-Host Mustafa Broachwala, DO, for a pivotal episode of the Pain Matters Podcast where we address the recent BMJ publication, “Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomized trials,” and the associated guideline. Steven Cohen, MD, Feinberg School of Medicine Northwestern University, Lynn R. Kohan, MD, University of VA Medical School, Zachary McCormick, MD, University of Utah, Nathaniel M. Schuster, MD, University of California, San Diego, Daniel Larach, MD, MS, MA, Vanderbilt University, Hance Clarke, MD, FRCPC, PhD, University of Toronto and President of the Canadian Pain Society, Hemant Kalia, MD, MPH, FIPP, Invision Health, and present diverse perspectives on the publication's claims and the systematic review and meta-analysis methods behind it.In this episode, you'll learn:The podcast underlines the necessity for comprehensive, unbiased systematic reviews and meta-analyses to inform clinical guidelines effectively.Experts caution against the misinterpretation of studies and the potential consequences for policy and access to interventional pain procedures.Advocates call for unified efforts in the pain medicine community to pursue legislative and regulatory reforms that align with current evidence and patient needs.The conversation underscores the pivotal role of personalized patient care and clinically validated techniques in improving outcomes and preserving practice legitimacy.The podcast highlights the risk of reducing access to viable interventional pain treatments if skewed interpretations of data shape healthcare policies.Tune in to discover how these leading experts address the controversies, advocate for robust clinical evidence, and highlight the urgent need for unified advocacy in shaping practical, patient-centered guidelines.Be sure to subscribe so you don't miss our next episode.Reference:  Wang X, Martin G, Sadeghirad B, Chang Y, Florez I D, Couban R J et al. Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials BMJ 2025; 388 :e079971 doi:10.1136/bmj-2024-079971

Join me for a fascinating conversation around an exciting breakthrough in dementia detection that's offering real hope for early intervention. Dr. Hans Frykman, Chief Scientific Officer at Neurocode Laboratories, is here to share groundbreaking insights into cutting-edge biomarkers that can identify pathology associated with Alzheimer's disease before symptoms even appear. What's even more fascinating is how these same tools are revealing neuroinflammation caused by infections, including COVID, Lyme disease, and mold exposure—issues that are incredibly relevant in functional medicine today. The assays Dr. Frykman and his team have developed, and continue to research, are transforming the way we think about diagnosing and addressing neurodegeneration. We're talking about a potential game-changer that allows us to intervene earlier, reverse damage, and ultimately improve the trajectory of these conditions. This is an extraordinary time in science and medicine, and the work we're discussing today is at the forefront of it all. Don't miss out on how this could reshape your practice. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr. Hans Frykman, MD PhD FRCPC hfrykman@neurocode.com Hans Frykman MD, Ph.D., FRCPC is the founder, CEO, and medical director of BC Neuroimmunology Lab located in the UBC hospital on the University of BC campus in Vancouver BC. He is the medical director for Lykke Lab a genetics laboratory also on the University of BC campus. Also, he is the CSO for Neurocode Lab Inc. in Bellingham WA, a high-complexity, specialty lab focused on neuroimmunology and biomarkers in neurodegeneration. Dr. Frykman has a clinical faculty position at the University of British Columbia, Faculty of Medicine, Division of Neurology. THANK YOU TO OUR SPONSORS DIAMOND DUTCH: https://dutchtest.com/for-providers Biotics Research: https://www.bioticsresearch.com/ GOLD TimeLine Nutrition: https://tinyurl.com/bdzx2xms Vibrant Wellness: https://www.vibrant-wellness.com/ EXCLUSIVE OFFERS FROM OUR SPONSORS OneSkin: Get 15% off OneSkin with the code DRKARA at oneskin.co/DRKARA Try Qualia NAD+ for up to 50% off! Visit http://qualialife.com/kara15 and use code KARA15 at checkout for an additional 15% off your entire purchase! Why MitoQ's mitochondria-targeting is a critical step for your healthspan and longevity strategy. https://tinyurl.com/2b5benmd Want more? CONNECT WITH DrKF Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we cover the recent approval of Genentech's tenecteplase, marketed as TNKase, as a new treatment for adults with acute ischemic stroke (AIS). The thrombolytic medicine is an intravenous tissue plasminogen activator that is clot-dissolving, administered as a single 5-second intravenous bolus. Tenecteplase is only the second such approval for this indication, following the 2015 approval of alteplase (Activase; Genentech); however, tenecteplase is considered faster and more simply administered than alteplase. To better understand the implications of this approval, NeurologyLive sat down with stroke expert Bijoy Menon, MD, MSc, FRCPC, a professor of neurology at the University of Calgary. In the interview, Menon talked about the downstream impacts of having another approved therapy, how tenecteplase differs from other thrombolytic agents, and the efficacy and safety that supported its approval. Furthermore, he provided commentary on how the approval continues to chip away toward the idea of precision medicine and personalizing treatments for patients with AIS.  For more of NeurologyLive's coverage of sodium oxybate's (Lumryz) expanded indication, head here: FDA Approves Tenecteplase for Acute Ischemic Stroke Episode Breakdown: 1:40 – Immediate reaction and significance of tenecteplase approval 5:30 – Safety considerations and administration when prescribing tenecteplase 10:20 – Supportive efficacy and safety, phase 3 AcT trial, and other supplementary studies 14:50 – Advancing precision medicine, treatment personalization with new approval Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment

Andrew Frank, MD, BScH, FRCPC - Decoding the Evidence Around Anti-Amyloid Therapies for Alzheimer's Disease: Expert Insights for Clinical Practice

Andrew Frank, MD, BScH, FRCPC - Decoding the Evidence Around Anti-Amyloid Therapies for Alzheimer's Disease: Expert Insights for Clinical Practice

In this episode Nicholas Chadi MD, MPH, FRCPC, FAAP, explains how pediatricians can help families avoid the misuse of prescription drugs. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to Michael Pitt, MD, FAAP, and Rheanne Maravelas, MD, about medical jargon and its effect on children's understanding. For resources go to aap.org/podcast.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SZN865. CME credit will be available until January 20, 2026.Individualized Treatment for Generalized Myasthenia Gravis: Targeting the Cause and Prioritizing the Patient In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Welcome to another episode of "Ditch the Labcoat," the podcast that brings a critical, science-based perspective to healthcare discussions. I'm your host, Dr. Mark Bonta, and today we dive deep into the intersection of nutrition and surgery. Joining us are Dr. Sagar Desai, an orthopedic surgeon, and Dr. Kyle Waldman, an anesthesiologist.We'll explore the influence of pharmaceutical companies in medicine, the importance of non-drug interventions, and how nutritional modifications can offer significant patient benefits. Our focus will be on immuno and pharmaco nutrition—innovative approaches combining amino acids, omega-3s, vitamins, and other nutrients to improve surgical outcomes and patient recovery.Sagar and Kyle will share their entrepreneurial journey with Proven Therapeutics, aiming to provide better perioperative care. We'll discuss the challenges of patient compliance, the evidence supporting these nutritional strategies, and the practicalities of implementing them in both academic and community settings.Plus, for a bit of levity, we'll be addressing some of the common stereotypes in the medical profession and the humorous side of our intense, life-saving work.So, grab your headphones and get ready to ditch the labcoat. Let's jump into a conversation that blends serious science with a touch of humor, all in the pursuit of better healthcare.06:21 - Unexpectedly switched career focus from orthopedics to internal medicine.09:32 - Steroids and diet significantly impact bowel surgery recovery.10:39 - Oral immunonutrition reduces the risk of anastomotic leaks.16:33 - Nutritional changes can outperform medications after heart attacks.17:26 - Nutrition data from general surgery applies to orthopedics as well.22:44 - Challenges and strategies for managing surgical anesthesia effectively.23:53 - Perioperative immunonutrition addresses the surgical stress response.28:12 - Evidence-based nutritional products are underutilized despite proven benefits.32:08 - Healthcare workers are genuinely dedicated to helping patients.37:18 - Thorough research ensures positive feedback on nutritional products.43:52 - Low financial risk, careful work, and significant patient benefits.45:29 - Enjoyable interviews with intellectual, humorous, and influential guests.47:28 - Evidence-based treatments are often overlooked in medical prescriptions.

Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

What's New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?

Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management

Nicholas Chadi MD, MPH, FRCPC, FAAP, joins host Dr. Edith Bracho-Sanchez to talk about the misuse of prescription medications. Some of the most commonly misused medications are those prescribed for attention-deficit/hyperactivity disorder (ADHD), pain relief, anxiety or sleep problems. When kids share or use them in ways other than prescribed, it can be dangerous. Learn ways to help prevent medication misuse and keep your child safe. 

In this episode, Dr Camidge sits down with Michael Smylie, MBBS, FRCPC, a professor in the Department of Oncology in the Faculty of Medicine and Dentistry at the University of Alberta and a medical oncologist at the Cross Cancer Institute in Edmonton, Canada.  Drs Camidge and Smylie discussed Dr Smylie's experience treating patients who live in the Northwest Territories of Canada, including the challenges he encounters when providing oncology care to such a vast geographic area, unique considerations when treating a predominantly indigenous community, and how his own colon cancer diagnosis influenced his relationship with patients.

On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Chung-Wai Chow, MD, PhD, FRCPC, to discuss the paper, “Pollution exposure in the first 3 months post transplant is associated with lower baseline FEV1 and higher CLAD risk.” Dr. Chow is a transplant pulmonologist and clinician scientist at the University of Toronto, with work focusing on investigating air pollution's impact on chronic lung diseases and developing improved methods to assess lung function. The episode explores: Measurement methods for home and personal air pollution exposures Specific pollutants like black carbon and their effects on patients after lung transplant Practical advice for mitigating these effects For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Those on heart transplant teams should tune in again later this month for a Scandinavian study that performs long-term follow ups with patients on the nephrotoxic effects of CNIs. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

This episode includes extended Q&A sessions that address your unanswered questions from the following presentations delivered at the 2024 Congress in Colorado Springs, Colorado:  (00:23) Panic On the Playground! Managing Social Anxiety in Pediatric Patients by Katherine Dahlsgaard, PhD, ABPP and Jeffrey Strawn, MD (Q&A with Dr. Dahlsgaard)   (15:12) Inflammatory Remarks: Our Evolving Understanding of the Role of Inflammation in Mental Health by Roger McIntyre, MD, FRCPC and Vladimir Maletic, MD, MS (Q&A with Dr. McIntyre)   (35:33) Wake Me Up Before You Go-Go: Strategies for Improving Sleep-Wake Issues by Thomas Schwartz, MD   (51:32) Beyond the Blues: Risk, Recognition, and Relief from Perinatal Mood and Anxiety Disorders by Lisa Tremayne, RN, PMH-C, CBC (lisa.tremayne@rwjbh.org)  Never miss an episode!

November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload technologies, the potency of new payloads, and bispecific targeting. Tolcher also shares what inspired him to pursue oncology, how he came across ADCs, and where he sees ADCs heading in the future.        LINKS:    Bionavigen NEXT Oncology 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WZX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 16, 2025.Using APOE as a Key in Alzheimer's Disease Treatment: Unlocking the Amyloid-Targeting Therapy Risk–Benefit Conundrum In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In this episode, host Shikha Jain, MD, speaks with Amita Patnaik, MD, FRCPC, about providing patient access to breakthrough drug developments, bringing early phase cancer trials to physicians and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Patnaik 0:21 •    The interview 1:23 •    How did you decide to become an oncologist, and how did you end up co-founding the START Center for Cancer Research?  1:32 •    Can you tell me about START's overarching purpose and where you see its need being most fulfilled? […] What do you hope START will accomplish in the next five to ten years?  11:33 •    How successful has START been at including underrepresented patient populations in clinical data? 17:52 •    What are some challenges you've found as you have navigated through founding a company and executing its mission? 21:48 •    What is next for you?  25:21 •    If someone else wanted to create a company like START, what are some tips you would give them?  27:23 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 32:03 •    How to contact Patnaik 34:44 •    Thanks for listening 35:27 Amita Patnaik, MD, FRCPC, is an internationally recognized medical oncologist and the co-founder of the START Center for Cancer Research. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Patnaik can be reached via email amita.patnaik@startresearch.com or via the START website.

Is the medical publishing industry a scam?  As the open access model has grown, pay-to-publish has helped large publishers maintain profit margins similar to that of large tech companies.  The problem?  They do so by exploiting the blood, sweat, and tears of academics and the institutions that support them.   Join Dr. Patrick Georgoff (@georgoff, Duke Surgery), Dr. Ayman Ali (BTK education fellow, Duke Surgery), and special guest Dr. Allan Detsky for an engaging discussion.  Paper discussed: The Changing Medical Publishing Industry: Economics, Expansion, and Equity (https://link.springer.com/article/10.1007/s11606-023-08307-z) DR. ALLAN S. DETSKY, MD, PhD, FRCPC, CM is Professor, Institute of Health Policy, Management and Evaluation, and Department of Medicine at the University of Toronto; former Physician-in-Chief, Mount Sinai Hospital(1997-2009); and former Head of the Division of General Internal Medicine at The Toronto Hospital and University of Toronto (1987-1997). Dr. Detsky received his B.S. from Massachusetts Institute of Technology, his M.D. from Harvard Medical School, and his Ph.D. (in Economics) from Massachusetts Institute of Technology in 1978.  He has served on the editorial board of the New England Journal of Medicine, and as a member of the Drug Quality and Therapeutics Committee for the Province of Ontario where he spearheaded the effort to formally include cost-effectiveness considerations into the Canadian drug reimbursement process. Dr. Detsky has received 2 Tony nominations as a producer (Jesus Christ Superstar 2012, Come From Away 2017 and an Olivier Award for Best Musical in 2018. In June 2018, he was appointed by the Governor General to the Order of Canada. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen